Complejo Hospitalario de Toledo -ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2022

  1. Multidisciplinary Consensus for the Management of Pulmonary Thromboembolism

    Archivos de Bronconeumologia

  2. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

  3. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Multidisciplinary consensus for the management of pulmonary thromboembolism

    Archivos de Bronconeumologia

  2. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

2020

  1. Results of an early access treatment protocol of daratumumab monotherapy in spanish patients with relapsed or refractory multiple myeloma

    HemaSphere, Vol. 4, Núm. 3

2019

  1. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

2017

  1. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

2012

  1. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma

    British Journal of Haematology, Vol. 158, Núm. 6, pp. 712-726

2010

  1. Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma

    Blood, Vol. 116, Núm. 8

2009

  1. Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications

    PLoS ONE, Vol. 4, Núm. 12